Tocilizumab
- Generic Name
- Tocilizumab
- Brand Names
- Actemra, RoActemra, Tyenne, Tofidence
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 375823-41-9
- Unique Ingredient Identifier
- I031V2H011
- Background
Tocilizumab is a recombinant humanized monoclonal antibody IL-6 receptor inhibitor used to treat inflammatory and autoimmune conditions. It was first described in the literature in 2003 when Chugai, a subsidiary of Roche began developing IL-6 inhibiting monoclonal antibodies. Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflamm...
- Indication
Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
...
- Associated Conditions
- Coronavirus Disease 2019 (COVID‑19), Cytokine Release Syndrome caused by CAR-T Cell Therapy, Giant Cell Arteritis (GCA), Juvenile Chronic Polyarthritis, Moderate to Severe Rheumatoid Arthritis, Moderately to Severely Active Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Systemic Juvenile Idiopathic Arthritis (SJIA), Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), Active systemic Juvenile idiopathic arthritis, Severe, active Rheumatoid arthritis
- Associated Therapies
- Monotherapy
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
- First Posted Date
- 2009-10-02
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT00988221
- Locations
- 🇦🇺
Princess Margaret Children'S Hospital; Department of Immunology, Subiaco, Western Australia, Australia
🇨🇦Alberta Children'S Hospital, Calgary, Alberta, Canada
🇨🇦Children'S Hospital of Eastern Ontario, Ottawa, Ontario, Canada
Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab
- Conditions
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Oklahoma
- Registration Number
- NCT00862758
- Locations
- 🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma CIty, Oklahoma, United States
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2016-02-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 286
- Registration Number
- NCT00754559
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2013-11-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 538
- Registration Number
- NCT00721123
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
- Conditions
- Interventions
- First Posted Date
- 2008-07-23
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2067
- Registration Number
- NCT00720798
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2007-09-26
- Last Posted Date
- 2017-07-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 132
- Registration Number
- NCT00535782
- Locations
- 🇺🇸
Rheumatology Associates of North Alabama, Huntsville, Alabama, United States
🇺🇸Pinnacle Research Group; Llc, Central, Anniston, Alabama, United States
🇺🇸Arthritis & Rheumatism; Disease Specialities, Aventura, Florida, United States
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 619
- Registration Number
- NCT00531817
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.